Fig. 2.

Treatment of mice carrying orthotopically transplanted Brca1^−/−;p53^−/− tumors with 50 mg of AZD2281 per kg i.p. (A) Intratumoral concentration of AZD2281 and PARP1 activity over time. Error bars indicate SEM. (B–D) Animals carrying 9 individually transplanted tumors (T1–T9) were either left untreated, or received AZD2281 daily for 28 or 100 days. Graphs show relative tumor volume (RTV, ratio of tumor volume to initial size at start of treatment) as a function of time. T8 and T9 showed stable disease and received continuous dosing beyond the 28 days (see Fig. S1). Once the tumors relapsed, treatment was resumed when the tumor size reached 100% of the original volume. Days on which AZD2281 was given are indicated by circles, triangles, or squares.